On October 17, 2017 Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) reported that new data investigating the use of eftilagimod alpha (IMP321), the Company’s lead product candidate, in combination with pembrolizumab in metastatic melanoma patients in Australia that have had either no response or a suboptimal response to pembrolizumab, will be presented in a poster presentation for the first time at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2017 Annual Meeting (Press release, Prima Biomed, OCT 17, 2017, View Source [SID1234520988]).

Pushing the accelerator and releasing the break: testing the soluble LAG-3 protein (IMP321), an antigen presenting cell activator, together with pembrolizumab in unresectable or metastatic melanoma. Poster Number P259
Authors: Victoria Atkinson, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Adnan Khattak, Christian Mueller, Tina Dunkelmann, Chrystelle Brignone, Frederic Triebel
The SITC (Free SITC Whitepaper) 2017 Annual Meeting is being held on November 10-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.